Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Chemotherapy for High Grade Upper Tract Urothelial Carcinoma
NCT02412670Phase 2Completed
- Sponsor
- ECOG-ACRIN Cancer Research Group
- Start
- Aug 2015
- Primary completion
- Aug 2018
- Modality
- DNA Intercalators/Alkylators, Targeted Liposomes, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of methotrexate, vinblastine, pegylated liposomal doxorubicin, Cisplatin micelle injection (HA132), gemcitabine in upper tract urothelial carcinoma (UTUC), sponsored by ECOG-ACRIN Cancer Research Group. Started Aug 2015; status: completed.
02
Drugs
methotrexatevinblastinepegylated liposomal doxorubicinCisplatin micelle injection (HA132)gemcitabine
03
Conditions
upper tract urothelial carcinoma (UTUC)
Beyond the preview
Go deeper on NCT02412670.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02412670.